GLP-1 Results for Black Women: What the Data Shows

If you're a Black woman considering GLP-1 medications like Semaglutide or Tirzepatide for weight loss, you're probably wondering: will this actually work for me?

It's a valid question. For too long, clinical trials have underrepresented Black women, leaving gaps in our understanding of how different medications perform across diverse populations. But the good news is that emerging data on GLP-1 results for Black women is painting an encouraging picture.

Let's look at what the research actually tells us about GLP-1 effectiveness in Black women, the unique health considerations to keep in mind, and what real-world results look like.

Understanding GLP-1 Medications and Why Representation Matters

GLP-1 receptor agonists—including Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound)—work by mimicking a natural hormone that regulates blood sugar and appetite. They've become breakthrough treatments for both type 2 diabetes and weight management.

But here's the challenge: historically, Black women have been significantly underrepresented in clinical trials. A 2019 analysis found that Black participants made up only about 8% of weight loss drug trials, despite Black women experiencing higher rates of obesity and related health conditions.

This representation gap matters because metabolic responses can vary across populations due to genetic, hormonal, and environmental factors. Thankfully, more recent studies are beginning to address this disparity.

What Clinical Trials Tell Us About GLP-1 Results for Black Women

Recent clinical data offers promising insights into how Black women respond to GLP-1 medications.

In the STEP trials examining Semaglutide, subgroup analyses included race-based outcomes. Black participants achieved significant weight loss, though some studies showed slightly lower percentage reductions compared to white participants. However, the differences were modest, and Black participants still experienced clinically meaningful results—typically losing 10-15% of body weight over 68 weeks.

The SURMOUNT trials for Tirzepatide showed similar patterns. Black women in these studies lost substantial weight, with many achieving the 15-20% weight loss range at the highest doses. Importantly, the medication was well-tolerated across racial groups.

A 2023 real-world study published in Obesity examined electronic health records from diverse patient populations. Black women using Semaglutide lost an average of 9.6% of their body weight over six months—results that align closely with overall population averages.

Why Results May Vary: Factors Affecting GLP-1 Effectiveness

Several factors can influence how individuals respond to GLP-1 medications, regardless of race:

• Starting weight and BMI: People with higher starting weights often see larger absolute weight loss numbers
• Adherence and dosage: Consistent use and proper dose escalation significantly impact results
• Lifestyle factors: Diet, physical activity, sleep, and stress management all play supporting roles
• Metabolic health status: Insulin resistance, PCOS, and thyroid conditions can affect outcomes
• Medication access and continuity: Interrupted treatment can slow or stall progress

For Black women specifically, some research suggests that higher rates of insulin resistance and hormonal conditions like PCOS may actually make GLP-1 medications particularly beneficial, since these drugs directly address insulin signaling.

Health Considerations Unique to Black Women

Black women face distinct health challenges that make effective weight management tools especially important.

Black women experience obesity at nearly twice the rate of white women (57% vs 40%, according to CDC data). This isn't about lifestyle choices—systemic factors including food access, healthcare disparities, chronic stress, and socioeconomic barriers all contribute.

Additionally, Black women have higher rates of conditions that GLP-1 medications can help manage:

• Type 2 diabetes (13% prevalence vs 8% in white women)
• Hypertension (44% vs 32% in white women)
• PCOS with metabolic complications

GLP-1 medications don't just support weight loss—they improve insulin sensitivity, reduce cardiovascular risk factors, and help manage blood sugar. For Black women facing elevated risks for these conditions, the benefits extend beyond the scale.

You can find more information about GLP-1 benefits and considerations on the ozarihealth.com/blog.

Real-World Results: What Black Women Are Experiencing

Beyond clinical trials, real-world evidence continues to build. Healthcare providers report that Black women using GLP-1 medications are seeing meaningful results when treatment is paired with appropriate support.

Success factors consistently include:

• Access to affordable medication (cost barriers disproportionately affect Black communities)
• Provider support and regular follow-up
• Culturally informed nutrition guidance
• Community and peer support
• Addressing side effects promptly

Many Black women report not just weight loss, but improvements in energy, mobility, blood pressure, and overall quality of life. These comprehensive benefits matter just as much as the number on the scale.

Making GLP-1 Therapy Work for You

If you're considering GLP-1 medication, here's how to set yourself up for success:

Find a provider who listens. You deserve care that acknowledges your unique health history and concerns. Ask questions, voice concerns, and expect respectful, thorough answers.

Address access barriers. Cost shouldn't prevent you from effective treatment. Compounded options and telehealth services have made GLP-1 medications more accessible than ever.

Commit to consistency. GLP-1 medications work best when taken regularly and given time to reach therapeutic levels.

Support your treatment. While these medications are powerful tools, pairing them with nourishing food choices, joyful movement, and stress management enhances results.

Track more than weight. Notice changes in how you feel, your energy levels, clothing fit, and health markers like blood pressure and blood sugar.

Key Takeaways

• Clinical and real-world data show that Black women achieve significant, meaningful weight loss with GLP-1 medications like Semaglutide and Tirzepatide
• While some studies show modest differences in percentage weight loss across racial groups, Black women consistently experience clinically important results—typically 10-20% body weight reduction
• Black women face higher rates of obesity and related metabolic conditions, making GLP-1 therapy particularly valuable for improving overall health outcomes
• Access to affordable medication, supportive providers, and consistent treatment are key factors for success

Frequently Asked Questions

Do GLP-1 medications work as well for Black women as for other groups?

Yes. Clinical trials and real-world data consistently show that Black women achieve significant weight loss and health improvements with GLP-1 medications. While some studies show slightly smaller percentage losses compared to white participants, Black women still typically lose 10-20% of body weight—results that are clinically meaningful and improve health outcomes. Individual results vary based on many factors including starting weight, adherence, dosage, and lifestyle factors.

Are there any safety concerns for Black women using GLP-1 medications?

GLP-1 medications have been well-tolerated across all racial groups in clinical trials. The most common side effects—nausea, digestive changes, and decreased appetite—occur similarly across populations. However, because Black women have higher rates of certain health conditions, it's especially important to work with a healthcare provider who monitors your individual response and adjusts treatment accordingly. Always disclose your complete medical history before starting any new medication.

Why haven't I heard more about GLP-1 results specifically for Black women?

Historically, clinical trials have underrepresented Black women, creating gaps in published data. However, this is changing. More recent studies are including diverse populations, and real-world evidence is growing as more Black women access these medications. The existing data is encouraging, showing that GLP-1 therapy is effective across racial groups. Continued research with diverse participants remains important for fully understanding how these medications work in different populations.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, prescribed by licensed providers and shipped to your door. Learn more at ozarihealth.com.

Reviewed by the Ozari Clinical Content Team (OCCT) — health writers and wellness professionals specializing in GLP-1 therapy and metabolic health. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.